

Elevated expression of transforming growth factor β 3 in carbon tetrachloride-treated rat liver and involvement of retinoid signaling

YOSHIHIRO MEZAKI¹, MAYAKO MORII², KIWAMU YOSHIKAWA¹, NORIKO YAMAGUCHI¹,
KIYOFUMI SATOYOSHI³, MITSUTAKA MIURA¹, KATSUYUKI IMAI¹, TATSUZO HEBIGUCHI²,
TOMONORI HABUCHI³ and HARUKI SENOO¹

Departments of ¹Cell Biology and Morphology, ²Pediatric Surgery and ³Urology, Akita University
Graduate School of Medicine, Akita 010-8543, Japan

Received July 30, 2011; Accepted September 13, 2011

DOI: 10.3892/ijmm.2011.809

Abstract. Transforming growth factor (TGF) β is a pro-fibrotic cytokine. While three isoforms (TGF- β 1, 2 and 3) are known, the functional differences between them are obscure. To investigate the roles of TGF- β isoforms during liver fibrogenesis, male Wistar rats were administrated carbon tetrachloride (CCl₄) subcutaneously twice a week for two months. Livers were excised and sectioned for histochemical examinations. These livers were also used to quantitate the expression of genes associated with fibrogenesis, including TGF- β isoforms, as well as those associated with retinoid metabolism. Expression levels of *Tgfb1* and *Tgfb3* were up-regulated in CCl₄-treated rat livers while that of *Tgfb2* was not changed. The mRNAs for lecithin-retinol acyltransferase (*Lrat*) and retinoic acid hydroxylase, *Cyp26a1*, were also elevated. By immunohistochemical staining, TGF- β 3 protein was found to be localized mainly in liver parenchymal cells (hepatocytes). These results indicate that retinoid mobilization likely takes place within the rat's liver following CCl₄ treatment, and suggest the possibility that the expression of *Tgfb* mRNA is regulated by retinoic acid receptors. Reporter analyses of a region of the *Tgfb3* gene were performed using the rat liver parenchymal cell line, RLC-16, and a positively responsive region was identified within its intron.

Introduction

Exposure to carbon tetrachloride (CCl₄) has hepatotoxic effects, including fatty degeneration and fibrosis. These

effects are initiated by highly reactive radicals such as CCl₃• and CCl₃OO•, which can modify DNA, lipids, protein and carbohydrates (1). These radicals also damage membranous structures, such as the plasma membrane, endoplasmic reticulum, mitochondria, and the Golgi apparatus through lipid peroxidation. These modifications of cellular components and organelles lead to a loss of Ca²⁺ homeostasis, reduced protein synthesis, apoptosis, and DNA mutation (1). Many factors, including cytokines, chemokines, NO, and bile acids are proposed to mediate the hepatotoxic effects of CCl₄ (2). Among those factors mediating CCl₄-induced fibrogenesis, TGF- β is the most important and well-studied cytokine (3-5). TGF- β was originally identified as a protein inducing anchorage-independent growth of non-neoplastic cells (6,7). It was later revealed to be involved in many cellular processes including cell proliferation, differentiation, motility, adhesion, and death. Mammalian TGF- β has three isoforms which are encoded by different genes and these three isoforms show similarities both structurally and functionally. TGF- β binds to specific receptors on the cell surface, and binding signals are transduced into the nucleus by Smad proteins. There, collagen gene expression is up-regulated, leading to the production and deposition of collagen proteins within the liver (5).

It is known that hepatic stellate cells, which reside within the perisinusoidal space between hepatic cords and liver sinusoidal endothelial cells, are involved in the fibrotic process (8,9). Another remarkable feature of hepatic stellate cells upon cirrhosis is the loss of vitamin A. However, the implication of this decrease in vitamin A within the liver is totally unknown. Vitamin A is obtained from foods in the form of the retinyl ester or β -carotene, and once converted to retinol in the intestine, it is carried in the bloodstream as retinyl ester to the liver, where it is stored for future usage (10,11). In target cells, vitamin A is converted to active metabolites (retinoids) which bind to nuclear transcription factors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), to activate transcription of their target genes (12,13) through retinoic acid response elements (RAREs) within gene promoters.

In this study of CCl₄-induced fibrosis of rat livers, we analyzed changes in mRNAs related not only to fibrogenesis,

Correspondence to: Dr Yoshihiro Mezaki, Department of Cell Biology and Morphology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
E-mail: mezaki@gipc.akita-u.ac.jp

Key words: liver, carbon tetrachloride, transforming growth factor β , vitamin A, retinoic acid receptor

but also to retinoid metabolism. A possible link between TGF- β signaling and retinoic acid signaling was also analyzed in this study.

Materials and methods

Materials. CCl₄, liquid paraffin, and all-trans retinoic acid (RA) were from Wako Pure Chemical (Osaka, Japan). Retinol (ROL) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were from Invitrogen (Carlsbad, CA, USA) and Vitromex (Vilshofen, Germany), respectively. Oligonucleotides were synthesized by Invitrogen. The mouse embryonal teratocarcinoma cell line, F9 (RCB1555), and the rat liver parenchymal cell line, RLC-16 (RCB1474) were provided by the RIKEN Cell Bank (Tsukuba, Japan).

Animals. Protocols for animal experimentation were approved by the Animal Research Committee, Akita University Graduate School of Medicine. All animal experiments adhered to the 'Guidelines for Animal Experimentation' of the University. Male Wistar rats, 6 weeks of age, and weighing between 165-175 g, were injected subcutaneously with 0.3 ml of CCl₄ per kg of body weight, in liquid paraffin (1:9 mixture), twice a week for two months (a total of 17 times). Rats were then anaesthetized, and livers were excised and immersed in 10% formalin for fixation and then embedded in paraffin for sectioning. For RNA preparation, small pieces of livers were quick-frozen in liquid nitrogen and kept frozen at -85°C. At the time of sacrifice, rats weighed 360-430 g.

RNA extraction and quantitative RT-PCR. Frozen rat livers were lysed in TRIzol reagent (Invitrogen), and total-RNA was isolated according to the manufacturer's protocols. Then, cDNAs were synthesized from 5 μ g of total-RNA using SuperScript III Reverse Transcriptase (Invitrogen) with an oligo(dT)18 primer. Quantification of cDNA was conducted with the LightCycler 480 SYBR-Green I Master (Roche Diagnostics, Meylan, France) according to the manufacturer's instructions. The primer sequences used are listed in Table I. PCR reactions were performed in triplicate, and standard deviations were calculated. Transcript amounts were normalized against the *Gapdh* transcript, and transcription levels in the normal liver were set to 1.0 for each gene.

The mouse embryonal teratocarcinoma cell line, F9, was cultured in RPMI-1640 medium supplemented with 10% FBS. RA in ethanol or ethanol alone was added to 10 cm culture dishes to a final concentration of 0.1 μ M. After 24 h cultivation, cells were treated as above with 2 ml of TRIzol reagent for quantification of mRNAs for *Tgfb1*, *Tgfb2*, *Tgfb3* and *Rarb*.

Immunohistochemistry. Paraffin-embedded livers were sectioned at 3 μ m intervals and de-paraffinized by immersion in xylene. Buffers were substituted sequentially with 100, 90, 80, 70 and 50% ethanol. Specimens were treated in boiled citrate buffer (0.01 M) in order to unmask the antigens and then cooled to room temperature. For inactivation of endogenous peroxidase activity, slides were immersed in 1% H₂O₂ for 20 min. Slides were treated with 2% bovine serum albumin (BSA) in phosphate-buffered saline containing 0.1% Tween-20 (PBST)

to block non-specific binding of antibodies. Slides were then incubated with rabbit polyclonal anti-TGF- β 1 antibody (1:50 dilution, sc-146, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or rabbit polyclonal anti-TGF- β 3 antibody (1:50 dilution, sc-82, Santa Cruz Biotechnology) in PBST plus 2% BSA for 2 h at room temperature. After washing, slides were treated with a 1:500 dilution of peroxidase-conjugated AffiniPure goat anti-rabbit IgG. After washing, slides were incubated with DAB substrate (Roche Diagnostics) for 30 min. Nuclei were counterstained with Mayer's hematoxylin solution (Wako Pure Chemical). Slides were washed with water and then immersed with 20, 40, 80 and 100% ethanol and finally, 100% xylene. Dried slides were sealed with Entellan new (Merck, Darmstadt, Germany) and recorded digitally using NanoZoomer Digital Pathology (Hamamatsu Photonics, Hamamatsu, Japan).

Plasmids. The genomic sequence of rat *Tgfb3* was obtained from the Ensembl database (ENSRNOT00000013516). The intronic sequence connecting exons 3 and 4 (4001-5390, numbers designate nucleotide positions within the intron) was amplified by PCR using a RoboCycler (Stratagene, La Jolla, CA, USA) with primers containing *KpnI* and *XhoI* overhangs and inserted in the pGL4.26 vector (Promega, Madison, WI, USA). The cloned fragment was verified by sequencing. There was an insertion of TGTGTG after 4087 and substitutions from A→G at 4156 and A→C at 5078. Though there is an insertion within the cloned fragments, we employed nucleotide numbering based on the database sequence. The reporter plasmid containing retinoic acid responsive element was used as a positive control as described elsewhere (14).

Mutagenesis of the cloned intronic sequence (putativeRARE) was performed as described (15) using the primer pairs CACTCCTGTAAAGACGCCACTATTGACCCAACC/GGTTGGGTCAATAGTGGCGTCTTTACAGGAGTG for putativeRAREm1, TAAAGACTGAACTATGCTCCCAACC TTCCTTC/GAAGTGAAGGTTGGGAGCATAGTTCAGT CTTTA for putativeRAREm2, and TAAAGACGCCACTAT GCTCCCAACCTTCACTTC/GAAGTGAAGGTTGGGAGC ATAGTGGCGTCTTTA for putativeRAREm12, respectively. Underlines indicate the mutated residues.

Transfection and luciferase assay. Transfection of plasmids into the rat liver parenchymal cell line RLC-16 was conducted with Lipofectamine 2000 reagent (Invitrogen). Two hundred and 50 ng of each reporter plasmid, pcDNA3.1-rRAR α and pcDNA3.1-rRXR α , along with 12.5 ng of pRL-CMV (Promega) as an internal control, were transfected in 12-well formats. Three hours after transfection, the medium was changed and ligands were added. Twenty-four hours after ligand addition, cells were lysed and luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega) with a luminescence reader (BLR-201, Aloka, Tokyo, Japan). Luciferase activity from the experimental reporter plasmid was normalized against luciferase activity from the control pRL-CMV plasmid in the same well. Three independent cultures were used for each luciferase assay, and the calculated standard deviations are indicated in the figures.

Statistical analysis. Statistical analyses were performed using the HulinKs KaleidaGraph software. Data are expressed as

Table I. Primers for RT-PCR.

Species	Gene	Forward	Reverse	Length (bp)
Rat	<i>Gapdh</i>	acagcaactcccattctcc	tccaccaccctgttgctgta	118
Rat	<i>Colla1</i>	acagtcgattcacttacagc	tgtccaaggagccacatcg	132
Rat	<i>Colla2</i>	attcactacactgtccttg	atgtccagaggtgcaatgctc	123
Rat	<i>Col3a1</i>	cacttacacagtcttagagg	atgtcataggggtgcgatatc	123
Rat	<i>Col4a1</i>	actacgcgaatgcttacagc	ctcatgcacacttggcagcg	130
Rat	<i>Tgfb1</i>	ccatgcccaacttctgtctggg	ggcacgcagcacgggtgatg	123
Rat	<i>Tgfb2</i>	cttatctgtggagttcagac	gccaatgtagtagaggatgg	134
Rat	<i>Tgfb3</i>	tacctcgcagctcagacac	ttctgccacatagtacaag	136
Rat	<i>Rxra</i>	cgggtctcagctactcgcgata	ctccacctattctcgttcc	108
Rat	<i>Rara</i>	ctgtttgctccaggagaagg	gaactgctgctctgggtctc	111
Rat	<i>Rarb</i>	ctctcaaagcctgcctcagt	cgagctcctcagagctggta	99
Rat	<i>Rarg</i>	cagccaaccctacatgttcc	tcgaggagtcgtcctcaaac	173
Rat	<i>Ppara</i>	atttcccttttgggtgctgc	tggttgctctgcaggtggag	125
Rat	<i>Pparb/d</i>	tcattgccgccatcattctg	ctgtcgggggtggtgacctg	124
Rat	<i>Pparg</i>	ggaattagatgacagtgact	gcctgcagcaggtgtcttg	117
Rat	<i>Cyp26a1</i>	aggctgatatgcaggcact	tggctcttcaaagtaagcc	170
Rat	<i>Lrat</i>	gcgaacactttgtgacctac	gacagctgaagcaagacaac	119
Rat	<i>Rbp4</i>	gttttctcgtgaccccaatg	actgttcttgagggtctgc	139
Rat	<i>Rbp1</i>	aggcatagatgaccgcaagt	tcataccctcaatccactg	117
Rat	<i>Crabp2</i>	tgtgcgaacagaggcttctg	ctcggacgtagacctggtg	129
Mouse	<i>Gapdh</i>	accacagtcctatgccatcac	cttggcagcaccagtggtatg	120
Mouse	<i>Tgfb1</i>	cctcatggccacccccctg	tcaatgtacagctgccgcacac	126
Mouse	<i>Tgfb2</i>	catatctatggagttcagac	tccaatgtaatagagaatgg	134
Mouse	<i>Tgfb3</i>	tacctcgcagcgcagacac	ttctccccacatagtacaag	136
Mouse	<i>Rarb</i>	same as the sequences for rat		

means \pm standard deviation (SD). The statistical significance of the differences was evaluated by the unpaired Student's t-test for data in Figs. 2 and 5 and by one-way analysis of variance (ANOVA) combined with the Tukey test for data in Fig. 4. P-values <0.05 were considered to be statistically significant.

Results

CCl₄-induced liver fibrosis. Liver fibrogenesis induced by chronic administration of CCl₄ was confirmed by Azan staining (Fig. 1). As was previously demonstrated, fibrotic areas were mainly distributed around central veins (Fig. 1C and D) and steatosis of parenchymal cells was also observed.

Expression of various genes involved in fibrogenesis as well as retinoid metabolism in CCl₄-treated rat liver. We quantified mRNA levels in the livers of normal and CCl₄-injected rats. We focused on genes associated with fibrogenesis, as well as those associated with retinoid metabolism, because it is known that retinoid loss is a frequently observed symptom in liver cirrhosis (8,9). As shown in Fig. 2, types I (*Colla1* and *Colla2*) and type III (*Col3a1*) collagen, which constitute a major portion of liver fibrosis, were up-regulated in CCl₄-treated rat livers. Type IV collagen (*Col4a1*), which is a main component of basal lamina, was also up-regulated. Among the TGF- β s, the most important cytokines for hepatic fibrogenesis, *Tgfb1*

and *Tgfb3* were up-regulated 2.4- and 7.1-fold, respectively, while *Tgfb2* was not significantly altered. *Rxra*, whose ligand is 9-*cis* retinoic acid, and *Rara*, *Rarb* and *Rarg*, whose ligand is all-trans retinoic acid, were all up-regulated in CCl₄-treated rat livers, though the increase in *Rara* was not significant. Peroxisome proliferator-activated receptors (*Ppara*, *Pparb/d*, *Pparg*), which are transcription factors responsible for lipid metabolism and energy consumption, were also up-regulated. *Cyp26a1*, the gene for a P450 enzyme, CYP26A1, which catalyzes hydroxylation of retinoic acid for its elimination, was greatly up-regulated. The gene for lecithin-retinol acyltransferase (*Lrat*), which esterifies retinol to make retinylesters, was also up-regulated. The genes encoding RBP (*Rbp4*), CRBP-I (*Rbp1*), and CRABP-II (*Crabp2*), which are serum retinol, cellular retinol, and cellular retinoic acid binding proteins, respectively, were slightly up-regulated in CCl₄-treated rat livers.

Immunohistochemical localization of TGF- β s in CCl₄-treated rat liver. Quantitative RT-PCR analyses revealed that TGF- β isoforms were differentially regulated in CCl₄-treated rat livers (Fig. 2). We thus used immunohistochemical methods to assess the localization of the TGF- β isoforms. Mature TGF- β isoforms are very similar to one another; TGF- β 3 is ~80% similar to TGF- β 1 and TGF- β 2, while TGF- β 2 is 72% similar to TGF- β 1 (16). Therefore, cross-reactivity of antibodies against TGF- β




Figure 1. Carbon tetrachloride (CCl_4)-induced liver fibrosis. Male Wistar rats were administered CCl_4 in liquid paraffin (C and D) or liquid paraffin alone (A and B) subcutaneously twice a week for two months. Livers were excised and sectioned for Azan staining. (B and D) Magnifications of central vein regions of panels (A) and (C), respectively. PV, portal vein; CV, central vein. Scale bars, $100 \mu\text{m}$.




Figure 2. Quantification of mRNAs for genes associated with fibrogenesis and retinoid metabolism. Livers from normal and CCl_4 -injected rats were analyzed for mRNA expression by quantitative RT-PCR using the primer sequences listed in Table I. Transcript levels were normalized against the *Gapdh* transcript, and the transcript levels of normal liver were set to 1.0 for each gene. * $p < 0.05$ vs. control.




Figure 3. Immunohistochemical staining of control (A and C) and CCl₄-injected (B and D) rat livers by sc-82 (A and B) or sc-146 (C and D) antibodies. The sc-82 antibody detects TGF-β1, -β2, and -β3 and the sc-146 antibody detects TGF-β1 and -β2. Nuclei were counterstained with hematoxylin. CV, central vein. Open arrows, parenchymal cells. Solid arrows, hepatic stellate cells. Open arrowheads, Kupffer cells. Solid arrowheads, endothelial cells. Red arrows, mesenchymal cells. Scale bars, 100 μm.

isoforms is very common. The commercially available anti-TGF-β1 antibody sc-146 (Fig. 3C and D) actually cross-reacts with TGF-β2, and antibody sc-82 (Fig. 3A and B), nominally an anti-TGF-β3 antibody, cross-reacts with both TGF-β1 and -β2, per the manufacturer. In spite of the cross-reactivity of the sc-146 antibody (which detects TGF-β1 and -β2), it stained very few cell types in CCl₄-treated rat liver sections (Fig. 3D) and almost none in normal rat liver sections (Fig. 3C). In CCl₄-treated rat livers, some non-parenchymal mesenchymal cells within pseudolobes or septa were positive for sc-146 staining (red arrows in Fig. 3D). Positive cells were more abundant in the central region than in the portal region, which is consistent with the fibrogenic tendency induced by CCl₄ (Fig. 1). Parenchymal cells (Fig. 3, open arrows), hepatic stellate cells (Fig. 3, solid arrows), Kupffer cells (Fig. 3, open arrowheads) and endothelial cells (Fig. 3, solid arrowheads) were generally negative for sc-146 staining both in normal and degenerated rat livers.

On the other hand, immunohistochemical staining by sc-82 antibody (which detects all three isoforms of TGF-β) showed strong staining of hepatocytes both in normal (Fig. 3A) and degenerated livers (Fig. 3B). Staining of non-parenchymal mesenchymal cells within the septa (Fig. 3B) was generally weak compared to that of hepatocytes. Taking into account the antibody specificity described above, strong staining of parenchymal cells in normal and CCl₄-treated rat livers is due to the presence of TGF-β3 in these cells. Parenchymal staining in CCl₄-injected livers was more intense than that in normal livers, which may reflect the induction of *Tgfb3* mRNA in CCl₄-treated rat livers (Fig. 2). Hepatic stellate cells (Fig. 3, solid arrows), Kupffer cells (Fig. 3, open arrowheads), endothelial cells (Fig. 3, solid arrowheads) seemed to be negative for sc-82 staining, though it was difficult to discriminate the cytoplasm of these cells from that of the parenchymal cells adjacent to these cells.

Retinoic acid-responsiveness of an intronic region of the Tgfb3 gene. TGF-β up-regulation in CCl₄-treated rat livers, especially the TGF-β3 isoform, as well as the up-regulation of genes associated with retinoid metabolism such as *Cyp26a1* and *Lrat*, led us to the idea that TGF-β expression may be regulated by retinoid signaling. Retinoic acid responsive elements were defined by either DR5 (direct repeat of (A/G)G(G/T)TCA intervened by any five nucleotides) or DR2 (direct repeat of (A/G)G(G/T)TCA with any two intervening nucleotides) elements. Therefore, we searched for such elements in the *Tgfb1* and *Tgfb3* genes. Within an intron, which intercalates between exons 3 and 4 of *Tgfb3*, a DR2 type of RARE 4322-GGGTCAatAGTTCA-4309 (numbers represent nucleotide positions within the intron and lower case letters indicate intervening nucleotides between two direct repeat sequences) was discovered (Fig. 4). A fragment containing this putative RARE was cloned and incorporated in a pGL4.26 vector (Fig. 4), which contained a minimal promoter between multiple cloning site and the luciferase gene. A defined sequence of the DR5 type of RARE was used as a positive control. As shown in Fig. 4, the region within intron 3-4 of the *Tgfb3* gene, which contains a putative DR2 type of RARE, was positively regulated by RA. This sequence was then mutated to GGGTCAatAGTGGC (putativeRAREm1), or GGGAGC atAGTTCA (putativeRAREm2), or GGGAGC atAGTGGC (putativeRAREm12), and these constructs were analyzed by the luciferase assay (Fig. 4). None of these mutants responded to RA, confirming that this specific element is responsible for the retinoid responsiveness within this DNA fragment.

Retinoic acid-mediated up-regulation of mRNAs for TGF-β isoforms in cultured cells. We also asked whether the DR2 element in the intronic region was present in the mouse *Tgfb3* gene and found that this element was conserved in rat and mouse (4392-GGGTCAaggAGTTCA-4379), though this element was




Figure 4. Exon-intron structure and retinoic acid-responsiveness of the rat *Tgfb3* gene. Upstream and downstream open boxes represent the 5'-untranslated region (UTR) and 3'-UTR, respectively. Seven closed boxes between two UTRs represent amino acid coding regions. A bold bar between exon 3 and 4 represents an intronic sequence used in the reporter assay. The intronic sequence was incorporated in pGL4.26 vector and transfected into a rat liver parenchymal cell line, RLC-16. Twenty-four hours after retinoid addition, cells were collected and luciferase activities were measured. The underlined sequence segments indicate the mutated residues. * $p < 0.05$ vs. control.




Figure 5. The effects of retinoid on gene expression of TGF- β isoforms in cultured cells. A mouse embryonal teratocarcinoma cell line, F9, was treated with 0.1 μ M all-trans retinoic acid (RA). After 24 h cultivation, cells were collected and assessed for mRNA expression by quantitative RT-PCR. Transcript levels were normalized against *Gapdh* transcript, and the transcript levels of control cells were set to 1.0 for each gene. As a representative RA-responsive gene, *Rarb* mRNA was quantified. * $p < 0.05$ vs. control.

not conserved in the human *Tgfb3* gene (data not shown). We then examined a mouse teratocarcinoma cell line F9 (positive for RAR α , β and γ), to determine whether the expression of TGF- β isoforms was altered in response to RA (Fig. 5). The mRNA levels for the *Rarb* gene, which has a definitive RARE in its promoter region, increased in RA-treated F9 cells, confirming the presence of retinoid-responsiveness in F9 cells used in this experiment. As shown in Fig. 5, minor increases in *Tgfb1* (1.2-fold) and *Tgfb3* isoforms (1.3-fold) were observed in RA-treated F9 cells, indicating that the expression of TGF- β isoforms was up-regulated to some extent in response to RA.

Discussion

Among TGF- β isoforms, TGF- β 1 protein was the first to be purified from human platelets (7), and the first to be cloned from human placenta (17). In the initial report describing *Tgfb1* cDNA cloning, several tissues and cell lines were assessed by Northern blotting. The liver was reported to be negative for *Tgfb1* mRNA (17). However, the same group later reported moderate expression of *Tgfb1* in rat liver (16). Another report using Northern blotting techniques stated that TGF- β 1 was the most abundant isoform in both normal and CCl₄-treated rat livers (18). The lowest level of *Tgfb1* mRNA was found in normal adult mouse liver, while neonatal mouse liver *Tgfb1* mRNA expression was 2-fold higher than in adult liver (19). By protein detection techniques such as immunohistochemistry, normal human livers were reported to be negative for TGF- β 1 staining, though fibrotic areas with chronic active hepatitis were positive for TGF- β 1 (20). Biliary ductular cells and hepatocytes of mouse liver were reported to be weakly positive for TGF- β 1 staining (19). From these earlier reports and our present data (Figs. 2 and 3), we speculate that in normal liver, very limited numbers of cells are positive for TGF- β 1, and in cirrhotic conditions, more cells become TGF- β 1-positive, though it is not certain if these TGF- β 1-positive cells develop within the liver or are derived from the circulation.

Using immunohistochemistry in this report, we showed that TGF- β 3 protein is widely distributed in hepatocytes (Fig. 3). We also showed increases in *Tgfb3* mRNA upon CCl₄ treatment, which was more prominent than the increase in *Tgfb1* mRNA (Fig. 2). The up-regulation of *Tgfb1* and *Tgfb3* mRNAs was also observed (though less prominently) following administration of RA in cultured cells (Fig. 5). By reporter analyses of an intronic region of *Tgfb3* gene, we found that the DNA fragment containing RARE responded positively to RA, suggesting that the up-regulation of *Tgfb3* mRNA was

partly mediated by retinoid signaling. The mechanism of up-regulation of *Tgfb1* mRNA upon CCl_4 treatment was not revealed in this report. It was reported that $\text{RAR}\alpha$, $\text{RAR}\beta$, and $\text{RXR}\alpha$ down-regulate the *Tgfb1* promoter by binding to AP-1 transcription factors, thus inhibiting their activities (21). It should also be noted that retinoid signaling can modify TGF- β activity indirectly. For example, retinoid signaling up-regulates TGF- β signaling by inducing the plasminogen activator, which proteolytically converts the latent form of TGF- β to an active form (22).

Several former reports stated the importance of TGF- β 3 in the pathogenesis of liver cirrhosis (23,24). Cirrhotic liver tissue samples from human patients showed increased expressions of *Tgfb1*, *Tgfb2* and *Tgfb3* mRNAs, of which *Tgfb3* showed the highest level of expression in human liver cirrhosis (23). The up-regulation of *Tgfb3* mRNA was also observed in livers of patients with primary biliary cirrhosis but not in livers of patients with viral cirrhosis (24). These earlier reports as well as our recent report (25) pointed out the possibility of the involvement of biliary epithelial cells in liver cirrhosis. Our present study showed the possibility that the hepatocytes are also involved in the pathogenesis of liver cirrhosis.

In summary, we show that TGF- β 3 is distributed in parenchymal cells in the liver and up-regulated in CCl_4 -treated rat livers. We propose that the increase of *Tgfb3* mRNA is partly mediated by retinoid signaling.

Acknowledgements

This study was supported by KAKENHI (23790269, 23792026 and 23590228).

References

- Weber LW, Boll M and Stampfl A: Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. *Crit Rev Toxicol* 33: 105-136, 2003.
- Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D and Lemasters JJ: Mechanisms of hepatotoxicity. *Toxicol Sci* 65: 166-176, 2002.
- Massague J: The transforming growth factor-beta family. *Annu Rev Cell Biol* 6: 597-641, 1990.
- Massague J: TGF-beta signal transduction. *Annu Rev Biochem* 67: 753-791, 1998.
- Inagaki Y and Okazaki I: Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. *Gut* 56: 284-292, 2007.
- Roberts AB, Anzano MA, Lamb LC, Smith JM and Sporn MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. *Proc Natl Acad Sci USA* 78: 5339-5343, 1981.
- Assoian RK, Komoriya A, Meyers CA, Miller DM and Sporn MB: Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. *J Biol Chem* 258: 7155-7160, 1983.
- Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* 275: 2247-2250, 2000.
- Senoo H and Wake K: Suppression of experimental hepatic fibrosis by administration of vitamin A. *Lab Invest* 52: 182-194, 1985.
- Napoli JL: Interactions of retinoid binding proteins and enzymes in retinoid metabolism. *Biochim Biophys Acta* 1440: 139-162, 1999.
- Blomhoff R and Blomhoff HK: Overview of retinoid metabolism and function. *J Neurobiol* 66: 606-630, 2006.
- Chambon P: A decade of molecular biology of retinoic acid receptors. *FASEB J* 10: 940-954, 1996.
- Kishimoto M, Fujiki R, Takezawa S, Sasaki Y, Nakamura T, Yamaoka K, Kitagawa H and Kato S: Nuclear receptor mediated gene regulation through chromatin remodeling and histone modifications. *Endocr J* 53: 157-172, 2006.
- Mezaki Y, Yoshikawa K, Yamaguchi N, Miura M, Imai K, Kato S and Senoo H: Rat hepatic stellate cells acquire retinoid responsiveness after activation in vitro by post-transcriptional regulation of retinoic acid receptor alpha gene expression. *Arch Biochem Biophys* 465: 370-379, 2007.
- Mezaki Y, Yamaguchi N, Yoshikawa K, Miura M, Imai K, Itoh H and Senoo H: Insoluble speckled cytosolic distribution of retinoic acid receptor alpha protein as a marker of hepatic stellate cell activation in vitro. *J Histochem Cytochem* 57: 687-699, 2009.
- Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL and Chen EY: A new type of transforming growth factor-beta, TGF-beta 3. *EMBO J* 7: 3737-3743, 1988.
- Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB and Goeddel DV: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. *Nature* 316: 701-705, 1985.
- De Bleser PJ, Niki T, Rogiers V and Geerts A: Transforming growth factor-beta gene expression in normal and fibrotic rat liver. *J Hepatol* 26: 886-893, 1997.
- Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB and Sporn MB: Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. *J Cell Biol* 108: 661-669, 1989.
- Nagy P, Schaff Z and Lapis K: Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. *Hepatology* 14: 269-273, 1991.
- Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P and Pfahl M: Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. *Mol Endocrinol* 7: 1347-1356, 1993.
- Okuno M, Moriwaki H, Imai S, Muto Y, Kawada N, Suzuki Y and Kojima S: Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. *Hepatology* 26: 913-921, 1997.
- Baer HU, Friess H, Abou-Shady M, Berberat P, Zimmermann A, Gold LI, Korc M and Buchler MW: Transforming growth factor betas and their receptors in human liver cirrhosis. *Eur J Gastroenterol Hepatol* 10: 1031-1039, 1998.
- Voumvouraki A, Koulentaki M, Tzardi M, Sfakianaki O, Manousou P, Notas G and Kouroumalis E: Increased TGF- β 3 in primary biliary cirrhosis: an abnormality related to pathogenesis? *World J Gastroenterol* 16: 5057-5064, 2010.
- Morii M, Mezaki Y, Yamaguchi N, Yoshikawa K, Miura M, Imai K, Yoshino H, Hebiguchi T, Hebiguchi T and Senoo H: Onset of apoptosis in the cystic duct during metamorphosis of a Japanese lamprey, *Lethenteron reissneri*. *Anat Rec (Hoboken)* 293: 1155-1166, 2010.